Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|January 31, 2019
Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centresHélène A Poirel, Marijke Vanspauwen, Gilles Macq, et al.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
Blood|January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.
The New England Journal of Medicine|April 6, 2017
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaMichel Attal, Valerie Lauwers-Cances, Cyrille Hulin, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Journal of Hematology & Oncology|January 7, 2024
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registryClaire Lacan, Jérôme Lambert, Edouard Forcade, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Blood|September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaAurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Pageof 10